Bristol Myers Squibb Terminates $1.6 Billion Deal, Returns TIGIT Rights to Agenus

Deal Termination::
Bristol Myers Squibb (BMS) has exited a $1.6 billion licensing agreement with Agenus for the development and commercialization of Agenus's anti-TIGIT therapy, AGEN1777.

Return of Rights::
BMS is handing back the rights to AGEN1777 to Agenus, marking the end of their collaboration on this specific project.

Notice Date::
Agenus received notice from BMS on July 30, 2024, regarding the termination of the agreement.

Impact::
This move signifies a significant shift in the strategic partnership between BMS and Agenus, potentially affecting the development timeline and commercial prospects of AGEN1777.